The impact of standard chemotherapy on miRNA signature in plasma in AML patients
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Validation Study
PubMed
26340914
DOI
10.1016/j.leukres.2015.08.009
PII: S0145-2126(15)30362-3
Knihovny.cz E-resources
- Keywords
- Acute myeloid leukemia, Liquid biopsy, Plasma, Remission, Standard chemotherapy, miRNA signature,
- MeSH
- Leukemia, Myeloid, Acute blood drug therapy genetics MeSH
- Cytarabine administration & dosage MeSH
- Adult MeSH
- Idarubicin administration & dosage MeSH
- Remission Induction MeSH
- Consolidation Chemotherapy MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Middle Aged MeSH
- Humans MeSH
- MicroRNAs biosynthesis blood genetics MeSH
- Mitoxantrone administration & dosage MeSH
- Pilot Projects MeSH
- Antineoplastic Combined Chemotherapy Protocols pharmacology therapeutic use MeSH
- Gene Expression Regulation, Leukemic drug effects MeSH
- RNA, Neoplasm biosynthesis blood genetics MeSH
- Transcriptome * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Validation Study MeSH
- Names of Substances
- Cytarabine MeSH
- Idarubicin MeSH
- MicroRNAs MeSH
- mirn199 microRNA, human MeSH Browser
- MIRN301A microRNA, human MeSH Browser
- MIRN326 microRNA, human MeSH Browser
- MIRN361 microRNA, human MeSH Browser
- MIRN625 microRNA, human MeSH Browser
- MIRN655 microRNA, human MeSH Browser
- Mitoxantrone MeSH
- RNA, Neoplasm MeSH
AIM: In our pilot study, we used plasma samples as liquid biopsy to search for miRNA signatures in patients with acute myeloid leukemia (AML) at diagnosis and in remission achieved after standard chemotherapy before planned transplantation. MATERIAL AND METHODS: We examined 10 plasma samples from healthy volunteers and 8 paired samples from patients with AML at diagnosis and in remission using TaqMan MicroRNA Arrays. The results were validated using single-target qPCR reactions run in triplicates. RESULTS: We selected 6 miRNAs with expressions significantly sensitive to therapy: miR-199b-5p, miR-301b, miR-326, miR-361-5p, miR-625 and miR-655. All selected miRNAs were not or very weakly expressed in healthy individuals. They were abundant in plasma in patients at diagnosis but their levels decreased after chemotherapy. CONCLUSION: We detected a therapy sensitive miRNA signature in plasma of patients with AML.
References provided by Crossref.org
